Kyverna Therapeutics, Inc. Capitalized Computer Software, Impairments
Kyverna Therapeutics, Inc. (KYTX) reported Capitalized Computer Software, Impairments of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CapitalizedComputerSoftwareImpairments1 · last filed 2026-08-11
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for the quarter ending 2026-06-30 was $0.00.
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for the quarter ending 2025-12-31 was $0.00.
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for the quarter ending 2025-09-30 was $0.00.
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for fiscal 2025 was $648.00K.
- Kyverna Therapeutics, Inc. capitalized computer software, impairments for fiscal 2024 was $0.00.
| Period end | Capitalized Computer Software, Impairments 3 month | Capitalized Computer Software, Impairments 6 month | Capitalized Computer Software, Impairments 9 month | Capitalized Computer Software, Impairments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $648.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $648.00K 10-Q · filed 2025-11-12 | $648.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $648.00K 10-Q · filed 2026-08-11 | $648.00K derived: sum of 3 quarters · filed 2026-08-11 | $648.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $648.00K 10-Q · filed 2026-05-12 | $648.00K derived: sum of 2 quarters · filed 2026-05-12 | $648.00K derived: sum of 3 quarters · filed 2026-05-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 10-K · filed 2026-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |